David M. Siegel, MD, PhD

David S. Siegel, MD, PhD, chief of the division of multiple myeloma at&nbsp;John Theurer Cancer Center, Hackensack Meridian Health,&nbsp;discusses one of the biggest dilemmas to arise recently in the treatment of multiple myeloma.

According to Siegel, there is a notion that it is imperative to change classes of drugs when there is progression of disease. This is believed by both community oncologists and myeloma experts alike.

Videos

David M. Siegel, MD, PhD, discusses one of the biggest dilemmas to arise recently in the treatment of multiple myeloma.

David M. Siegel, MD, PhD | Authors

Articles

Expert Addresses Major Challenge in Treatment of Myeloma